<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04055532</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00007108</org_study_id>
    <nct_id>NCT04055532</nct_id>
  </id_info>
  <brief_title>Biomarkers in Neurodegenerative Diseases</brief_title>
  <official_title>Biomarkers in Neurodegenerative Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general purpose of this observational study is to examine biomarkers associated with the
      pathology of neurodegenerative diseases to potentially develop novel therapeutic approaches.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of regulatory approval
  </why_stopped>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Performance on Batteries of Cognitive Tests</measure>
    <time_frame>2-5 Years</time_frame>
    <description>Performance on batteries of cognitive tests as measured by the Modified Autobiographical Memory Interview (MAMI), Stroop Test, CDR-SOB, Spontaneous Speech Test, and the Neuropsychological Battery from the Uniform Data Set.</description>
  </primary_outcome>
  <number_of_groups>11</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Mild Cognitive Impairment (MCI)</condition>
  <condition>Alzheimer Disease (AD)</condition>
  <condition>Dementia With Lewy Bodies (DLB)</condition>
  <condition>Frontotemporal Lobar Degeneration (FTLD)</condition>
  <condition>Parkinsons Disease With Dementia (PDD)</condition>
  <condition>Transient Epileptic Amnesia (TEA)</condition>
  <condition>Temporal Lobe Epilepsy (TLE)</condition>
  <condition>Spinocerebellar Ataxias (SCA)</condition>
  <condition>HIV Associated Neurocognitive Disorder (HAND)</condition>
  <condition>Amyotrophic Lateral Sclerosis (ALS)</condition>
  <condition>Primary Lateral Sclerosis (PLS)</condition>
  <arm_group>
    <arm_group_label>Mild Cognitive Impairment</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Alzheimer's Disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Dementia with Lewy Bodies</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Frontotemporal Lobar Dementia</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Parkinson's Disease with Dementia</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Transient Epileptic Amnesia</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Temporal Lobe Epilepsy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Spinocerebellar Ataxia</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-Associated Neurocognitive Disorder</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Amyotrophic Lateral Sclerosis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary Lateral Sclerosis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neuraceq</intervention_name>
    <description>Neuraceq is a radioactive isotope used for Amyloid-beta-PET/CT scans.</description>
    <arm_group_label>Alzheimer's Disease</arm_group_label>
    <arm_group_label>Amyotrophic Lateral Sclerosis</arm_group_label>
    <arm_group_label>Dementia with Lewy Bodies</arm_group_label>
    <arm_group_label>Frontotemporal Lobar Dementia</arm_group_label>
    <arm_group_label>HIV-Associated Neurocognitive Disorder</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment</arm_group_label>
    <arm_group_label>Parkinson's Disease with Dementia</arm_group_label>
    <arm_group_label>Primary Lateral Sclerosis</arm_group_label>
    <arm_group_label>Spinocerebellar Ataxia</arm_group_label>
    <arm_group_label>Temporal Lobe Epilepsy</arm_group_label>
    <arm_group_label>Transient Epileptic Amnesia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  Adults lacking capacity to consent and/or adults with diminished capacity to consent,
             including, but not limited to, those with acute medical conditions, psychiatric
             disorders, neurologic disorders, developmental disorders, and behavioral disorders.

          -  Individual or group with a serious health condition for which there are no
             satisfactory standard treatments.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of MCI, AD, DLB, FTLD, PDD, TEA, TLE, SCA, HAND, ALS, PLS, or normal
             control.

          2. Age 18 or older

          3. Reliable informant with frequent contact with participant

          4. Mini Mental State Exam (MMSE) â‰¥15 AND/OR Clinical Dementia Rating (CDR) less than 2

          5. Able to undergo extensive psychometric testing

        Exclusion Criteria:

          1. Any conditions that could account for cognitive deficits in addition to a
             neurodegenerative disease, including but not limited to:

               -  Past or present diagnosis of Korsakoff's syndrome

               -  Alcohol or substance abuse preceding dementia &amp; still present within 5 years of
                  onset

               -  Present untreated vitamin B12 or folate deficiency

               -  Present untreated hypothyroidism

               -  Past or present head trauma with persistent deficits

               -  Present untreated syphilis

               -  Past or present multiple sclerosis or another neuro-inflammatory disorder

               -  Past or present vascular or multi-infarct dementia

               -  Past or present diagnosis of huntington's disease

               -  Past or present normal pressure hydrocephalus

               -  Past or present central nervous system (CNS) lesions deemed to be clinically
                  significant

               -  Unresolved or present subdural hematoma

               -  Past or present Ischemic Vascular Dementia

               -  Past or present intracerebral hemorrhage

               -  Present systematic liver disease

               -  Present renal insufficiency requiring dialysis

               -  Present encephalitis or meningitis

               -  Present anxiety disorder (not due to dementia and requiring medication more than
                  3x per week)

               -  Present severe periventricular white matter disease or greater than grade 4 white
                  matter lesions

               -  Present lacunar infarcts deemed to clinically significant

               -  Present cortical stroke

               -  Present respiratory condition requiring oxygen

          2. Present significant systemic medical illness, such as cancer requiring chemotherapy or
             end stage cardiac insufficiency

          3. Present inability to safely scan in an MRI

          4. Present pregnancy or lactation - Female participants will be asked to confirm that
             they are not pregnant and do not plan to become pregnant.

          5. Present current medication likely to affect CNS functions:

               -  Benzodiazepines (no triazolam, but other short-acting benzodiazepines are OK)

               -  Antidepressant therapy with amitriptyline or doxepin or tx not stable during past
                  year

               -  Neuroleptics in the phenothiazine and haloperidol families (atypicals OK)

               -  Narcotics (codeine is OK, but hold 24 hours before neuropsychological testing)

               -  Anti-seizure medication outside of therapeutic ranges

               -  Antihistamines (&gt; 3x per week; hold 24 hours before neuropsychological testing)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Keith Vossel, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
    <mesh_term>Spinocerebellar Ataxias</mesh_term>
    <mesh_term>Spinocerebellar Degenerations</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
    <mesh_term>Epilepsy, Temporal Lobe</mesh_term>
    <mesh_term>Amnesia</mesh_term>
    <mesh_term>Frontotemporal Lobar Degeneration</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Neurocognitive Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

